SPAC for 2025 BLA: Non-vi­ral gene ther­a­py biotech en­Gene, steered by ex-Myth­ic lead­ers, finds For­bion blank check

Near­ing a Phase II for its non-vi­ral gene ther­a­py, a small Cana­di­an biotech plans to com­bine with a For­bion-led blank check …

Endpoints News

Sign up to read this article for free.

Get free access to a limited number of articles, plus choose newsletters to get straight to your inbox.